Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclatasvir and Asunaprevir in Treatment-naive Chronic Hepatitis C Genotype 1b
NCT02496078Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of daclatasvir, asunaprevir in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Started Aug 2015; status: completed.
02
Drugs
daclatasvirasunaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02496078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02496078.